journal article·2025-12Open access

CDH1 Orchestrates Anabolic Events to Promote Cell Cycle Initiation

Yun‐Zi Mao, Jiao‐Jiao Zhang, Meng‐Qi You, Han Wang, Yan Lin, Yuan Fang, Hui‐Lu Zhang, Yuan‐Yuan Qu, Qian Zhou, Meng Wang, Gang Li, Zi‐Fan Guo, Meng Xu, Jie Liu, Peng‐Cheng Lin, Yi‐Yuan Yuan, Yu Kang, Shi‐Min Zhao, Wei Xu

Advanced Science· Volume 12· Issue 47

Abstract

Abstract Cell proliferation requires anabolic supports. How the cell cycle integrates anabolism remains poorly understood. Herein, it is identified that G1‐phase regulator cell division cycle 20‐like protein 1 (CDH1) coordinates anabolic events to ensure cell cycle initiation. CDH1 degrades Von Hippel–Lindau (VHL), concomitantly activates hypoxia‐inducible factor 1α (HIF1 α ), which enhances angiogenesis and glucose metabolism, and activates mitochondrial lactyltransferase alanyl tRNA synthetase (AARS2), which lactylates and inactivates pyruvate dehydrogenase E1 subunit alpha 1 (PDHA1), thereby conserving anabolites. Among the CDH1‐accumulated anabolites, ribose‐5‐phosphate (R5P) binds to transketolase‐like‐1 (TKTL1) to bridge CDH1 to cyclin‐dependent kinase 2 (CDK2) and Skp1‐Cullin‐F‐box and β ‐transducin repeat‐containing protein (SCF β ‐TRCP ) complex, thereby facilitating CDH1 phosphorylation and degradation to promote cell cycle initiation. This CDH1‐VHL‐HIF1 α /AARS2‐R5P/TKTL1 circuit is supported by the observation that low R5P levels and high CDH1 expression correlate with proliferating cancer cells and tissues. Moreover, it is demonstrated that an artificial R5P signal, generated by ribose‐5‐sulfate (R5S), sensitizes cancer cells to apoptosis by initiating the cell cycle in the absence of sufficient anabolite supply. These suggest that cancer signatures, including the Warburg effect and angiogenesis, are intrinsically driven by CDH1.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Cancer, Hypoxia, and Metabolism · RNA modifications and cancer · Metabolism, Diabetes, and Cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The Obstetrics and Gynecology Hospital of Fudan University Shanghai Key Lab of Reproduction and Development Shanghai Key Lab of Female Reproductive Endocrine Related Diseases, Shanghai Key Laboratory of Metabolic Remodeling and Health State Key Laboratory of Genetics and Development of Complex Phenotypes, and Institutes of Biomedical Sciences, Fudan Unviersity Shanghai 200433 China

Shanghai Institute of Endocrine and Metabolic Diseases Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai 200025 China

Department of Liver Surgery Zhongshan Hospital of Fudan University Shanghai 200032 China

Department of Digestive Diseases Huashan Hospital of Fudan University Shanghai 200040 China

Department of Urology Fudan University Shanghai Cancer Center, Fudan University Shanghai 200032 China

Key Laboratory for Tibet Plateau Phytochemistry of Qinghai Province, College of Pharmacy Qinghai University for Nationalities Xining 810007 China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China

References (34)

Show source-provided references
1. 10.1016/j.cell.2011.02.01310.1016/j.cell.2011.02.013 ↗
2. 10.1101/gad.14.16.198310.1101/gad.14.16.1983 ↗
3. 10.1097/CCO.0b013e32835b651e10.1097/CCO.0b013e32835b651e ↗
4. 10.1016/S0092-8674(00)80108-710.1016/S0092-8674(00)80108-7 ↗
5. 10.1016/j.yexcr.2005.11.01510.1016/j.yexcr.2005.11.015 ↗
6. 10.1002/path.168610.1002/path.1686 ↗
7. 10.1074/jbc.M01014420010.1074/jbc.M010144200 ↗
8. 10.1158/0008-5472.CAN-11-145710.1158/0008-5472.CAN-11-1457 ↗
9. 10.1593/neo.9135410.1593/neo.91354 ↗
10. 10.3389/fonc.2016.0004110.3389/fonc.2016.00041 ↗
11. 10.1038/emboj.2012.7110.1038/emboj.2012.71 ↗
12. 10.1042/BJ2012042710.1042/BJ20120427 ↗
13. 10.1038/ncb0708-75510.1038/ncb0708-755 ↗
14. 10.1016/S0092-8674(03)00232-010.1016/S0092-8674(03)00232-0 ↗
15. 10.1016/S0960-9822(99)80290-510.1016/S0960-9822(99)80290-5 ↗
16. 10.1074/jbc.270.40.2358910.1074/jbc.270.40.23589 ↗
17. 10.1016/j.celrep.2013.07.03110.1016/j.celrep.2013.07.031 ↗
18. 10.1038/s41422-023-00864-610.1038/s41422-023-00864-6 ↗
19. 10.1016/j.stem.2022.03.00910.1016/j.stem.2022.03.009 ↗
20. 10.1074/jbc.M21107820010.1074/jbc.M211078200 ↗
21. 10.1093/oxfordjournals.jbchem.a02273010.1093/oxfordjournals.jbchem.a022730 ↗
22. 10.1038/s41467-019-10375-x10.1038/s41467-019-10375-x ↗
23. 10.1038/s41568-021-00388-410.1038/s41568-021-00388-4 ↗
24. 10.1007/s40265-014-0212-x10.1007/s40265-014-0212-x ↗
25. 10.1038/s41568-023-00557-710.1038/s41568-023-00557-7 ↗
26. 10.1042/BJ2013015310.1042/BJ20130153 ↗
27. 10.1038/onc.2010.39510.1038/onc.2010.395 ↗
28. 10.1038/s41419-020-2493-110.1038/s41419-020-2493-1 ↗
29. 10.1309/AJCPRHM8CZH5EMFD10.1309/AJCPRHM8CZH5EMFD ↗
30. 10.1016/j.cell.2016.05.07710.1016/j.cell.2016.05.077 ↗
31. 10.1016/j.tcb.2021.05.00110.1016/j.tcb.2021.05.001 ↗
32. 10.1074/jbc.M60658920010.1074/jbc.M606589200 ↗
33. 10.1093/nar/gkv04710.1093/nar/gkv047 ↗
34. 10.2353/ajpath.2007.06076710.2353/ajpath.2007.060767 ↗